Redmile Group, LLC 13D and 13G filings for Fate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-03 4:01 pm Purchase | 2025-07-02 | 13D | Fate Therapeutics, Inc. FATE | Redmile Group, LLC | 17,941,579 14.900% | 124,945 (+0.70%) | Filing |
| 2024-12-26 9:00 pm Purchase | 2024-12-20 | 13D | Fate Therapeutics, Inc. FATE | Redmile Group, LLC | 17,816,634 14.900% | 197,539 (+1.12%) | Filing |
| 2024-03-25 5:15 pm Purchase | 2024-03-21 | 13D | Fate Therapeutics, Inc. FATE | Redmile Group, LLC | 17,619,095 14.900% | 2,569,256 (+17.07%) | Filing |
| 2023-12-28 4:53 pm Sale | 2023-12-26 | 13D | Fate Therapeutics, Inc. FATE | Redmile Group, LLC | 15,049,839 14.900% | -21,257 (-0.14%) | Filing |
| 2023-04-19 5:15 pm Purchase | 2023-04-13 | 13D | Fate Therapeutics, Inc. FATE | Redmile Group, LLC | 15,071,096 14.900% | 2,077,208 (+15.99%) | Filing |